Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival

详细信息    查看全文

• 作者：Wenfeng Li (1)
  Zhengyang Xu (2)
  Junfeng Hong (3)
  Yunsheng Xu (4)
  
• 关键词：Esophageal squamous cell carcinoma ; PKM2 ; HK1 ; PFKB
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：31
• 期：9
• 全文大小：934 KB
• 参考文献：1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400-2. CrossRef
  2. Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179-3. CrossRef
  3. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417-2. CrossRef
  4. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193-. CrossRef
  5. Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73-4.
  6. Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625-. CrossRef
  7. Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111-.
  8. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013;45:e45. CrossRef
  9. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312. CrossRef
  10. Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687-7. CrossRef
  11. Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18-7.
  12. Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333-2. CrossRef
  13. Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14. CrossRef
  14. Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle. 2013;12(19):3154-. CrossRef
  15. Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510-. CrossRef
  16. Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917-2. CrossRef
  17. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340-2. CrossRef
  18. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell.?2014;53(1):75-7.
  19. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892-. CrossRef
  20. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7-):1358-6. CrossRef
  21. Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.1007/s10238-013-0250-9 .
  22. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797-02. CrossRef
  23. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232. CrossRef
  24. Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355-0.
  25. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438-5. CrossRef
  26. Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357-3. CrossRef
  27. Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99. CrossRef
  
• 作者单位：Wenfeng Li (1)
  Zhengyang Xu (2)
  Junfeng Hong (3)
  Yunsheng Xu (4)
  
  1. Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang, China
  2. Department of Chemo-Radiotherapy, The People’s Hospital of Yinzhou District, Ningbo, 315000, Zhejiang, China
  3. Department of Ultrosound, Fuzhou General Hospital of PLA, Fuzhou, 350025, Fujian, China
  4. Department of Dermatovenereology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang, China
  
• ISSN：1559-131X

文摘

Enhanced glycolysis is a common trait of many types of human cancers. This study was to detect the expression pattern of three regulatory enzymes during glycolysis in esophageal squamous cell carcinoma (ESCC) and to investigate their correlation with patients-outcome based on banked pathology material. A total of 141 surgically resected specimens of primary ESCC patients without prior treatments were retrospectively recruited from the First Affiliated Hospital of Wenzhou Medical College Hospital from 2007 to 2009. Expression of HK1, PFKB, and PKM2 in ESCC specimens was analyzed by immunohistochemical staining and Western blotting analysis. HK1-shRNA was used to knock down HK1 expression in ESCC cells, and the functional significance was assessed by CCK8 assay. It was found that the expression of two glycolytic enzymes, HK1 and PKM2, was associated with disease progression, invasion, and poor survival of patients with ESCC. Silence of HK1-inhibited cell proliferation in vitro and suppressed phospho-S6 kinase expression. Our findings suggest that activation of key enzymes in glycolysis might serve as potential therapeutic targets and/or prognostic factors for patients with ESCC.